Gene · 1633
Papers2,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,658
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DNA polymerases in precise and predictable CRISPR/Cas9-mediated chromosomal rearrangements. | BMC Biol | 2023 | 38066536 | PubTator, text mining | PubMed |
| Epigenome-Driven Strategies for Personalized Cancer Immunotherapy. | Cancer Manag Res | 2023 | 38058537 | PubTator, text mining | PubMed |
| Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials. | Eur J Med Res | 2023 | 38053150 | PubTator, text mining | PubMed |
| Enhancing the anticancer potential of metformin: fabrication of efficient nanospanlastics, in vitro cytotoxic studies on HEP-2 cells and reactome enhanced pathway analysis. | Int J Pharm X | 2023 | 38024451 | PubTator, text mining | PubMed |
| CD147: an integral and potential molecule to abrogate hallmarks of cancer. | Front Oncol | 2023 | 38023152 | PubTator, text mining | PubMed |
| Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment. | Molecules | 2023 | 38005235 | PubTator, text mining | PubMed |
| 8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML Treatment. | Biomolecules | 2023 | 38002257 | PubTator, text mining | PubMed |
| A new technique for the analysis of metabolic pathways of cytidine analogues and cytidine deaminase activities in cells. | Sci Rep | 2023 | 37993628 | PubTator, text mining | PubMed |
| Establishment and verification of a prognostic risk score model based on immune genes for hepatocellular carcinoma in an Asian population. | Transl Cancer Res | 2023 | 37969383 | PubTator, text mining | PubMed |
| Integrating [18F]-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors. | Cancers (Basel) | 2023 | 37958353 | PubTator, text mining | PubMed |
| Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements. | Cureus | 2023 | 37954763 | PubTator, text mining | PubMed |
| A Metabolic Gene Survey Pinpoints Fucosylation as a Key Pathway Underlying the Suppressive Function of Regulatory T Cells in Cancer. | Cancer Immunol Res | 2023 | 37933083 | PubTator, text mining | PubMed |
| Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study. | Front Pharmacol | 2023 | 37920204 | PubTator, text mining | PubMed |
| HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes. | Viruses | 2023 | 37896768 | PubTator, text mining | PubMed |
| Purine metabolism-related genes and immunization in thyroid eye disease were validated using bioinformatics and machine learning. | Sci Rep | 2023 | 37884559 | PubTator, text mining | PubMed |
| Time trend and seasonality in medically attended respiratory syncytial virus (RSV) infections in US children aged 0-5 years, January 2010-January 2023. | Fam Med Community Health | 2023 | 37844966 | PubTator, text mining | PubMed |
| H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagy. | Clin Transl Med | 2023 | 37837401 | PubTator, text mining | PubMed |
| Polymer-Based Nanoparticles as Drug Delivery Systems for Purines of Established Importance in Medicine. | Nanomaterials (Basel) | 2023 | 37836288 | PubTator, text mining | PubMed |
| Exosomes: Emerging Modulators of Pancreatic Cancer Drug Resistance. | Cancers (Basel) | 2023 | 37835408 | PubTator, text mining | PubMed |
| Association of COVID-19 with respiratory syncytial virus (RSV) infections in children aged 0-5 years in the USA in 2022: a multicentre retrospective cohort study. | Fam Med Community Health | 2023 | 37832975 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1633/papers?page=5